Brian Mansel Richards

CeNeS Pharmaceuticals Plc engages in the discovery and development of drugs. The company was founded by Alan Gilbert Goodman in 1997 and is headquartered in Cambridge, the United Kingdom.

Acambis Plc develops biopharmaceutical products and vaccines. It offers ACAM2000, a smallpox vaccine for emergency-use stockpiling; and ChimeriVax-JE, a single-dose Japanese encephalitis vaccine for endemic markets and travelers. Its products in pipeline include ChimeriVax-JE, ChimeriVax-West Nile, and ChimeriVax-Dengue. The company was founded in 1992 and is headquartered in Cambridge, UK.

Cozart Ltd. designs and manufactures diagnostics products. Its products are used to test for the presence of various drugs of abuse, such as opiates, cocaine, amphetamine, methamphetamine and cannabis. The company also offers laboratory services providing screening and confirmation services in samples including oral fluid, urine, and blood. Cozart was founded by Dr. Christopher William Hand and Philip Hand in 1993 and is located in Abingdon, the United Kingdom.

Summit Therapeutics Ltd. operates as a holding company, which engages in the discovery, development, and commercialization of antibiotic medicines. The company seeks to expand its product candidate portfolio through the development of new mechanism and precision antibiotics. Summit Therapeutics was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, the United Kingdom.

Alizyme Plc was engaged in the development of pharmaceutical products for the diseases related to obesity treatment. The company was founded in 1995 and was headquartered in Cambridge, the United Kingdom.

Handex Consulting & Remediation LLC provides environmental services. It offers remediation, regulatory support, risk management, waste mineralization, health & safety training, data support, as well as engineering and construction services. Its customers include Exxon Mobil, Lockheed Martin and Verizon. The company was founded in 1968 and is headquartered in Mount Dora, FL.

Xenetic Biosciences (UK) Ltd. is engaged in the development of drug and vaccine delivery systems and proprietary products in the fields of protein drugs, vaccines and oncology. It provides specialist delivery solutions to improve the efficacy and performance of drugs and vaccines in a number of key medical areas including oncology. The company's product pipeline includes polyxen, imuxen and oncohist. Xenetic Biosciences was founded by Gregory Gregoriadis on June 24, 1996 and is headquartered in London, the United Kingdom.